Nanoparticle-Based Oral Drug Delivery System for an Injectable Antibiotic – Streptomycin

Abstract

Background: To develop an oral drug delivery system for an injectable antibiotic, streptomycin. Methods: Poly-lactide-co-glycolide (PLG) nanoparticles encapsulating streptomycin were prepared by the multiple emulsion technique and administered orally to mice for biodistribution and chemotherapeutic studies. Results: The mean particle size was 153.12 nm with 32.12 ± 4.08% drug encapsulation and 14.28 ± 2.83% drug loading. Streptomycin levels were maintained for 4 days in the plasma and for 7 days in the organs following a single oral administration of PLG nanoparticles. There was a 21-fold increase in the relative bioavailability of PLG-encapsulated streptomycin compared with intramuscular free drug. In Mycobacterium tuberculosis H₃₇Rv infected mice, eight doses of the oral streptomycin formulation administered weekly were comparable to 24 intramuscular injections of free streptomycin. Further, the nanoparticle formulation did not result in nephrotoxicity as assessed on a biochemical basis. Conclusion: Our results suggest that nanoencapsulation might be useful for developing a suitable oral dosage form for streptomycin and perhaps for other antibiotics that are otherwise injectable.

Biogenic Synthesis of Nanoparticles and Potential Applications: An Eco- Friendly Approach

“…Pandey and Khuller [89] designed nanoparticle for the growth of oral drug delivery system, and recommended that nano-encapsulation may be useful for developing an appropriate oral dosage form for streptomycin, and for other antibiotics that are, if not injectable [89]. Elechiguerra et al [90] demonstrated the interaction of metal nanoparticles with viruses and explained that silver nanoparticles experience a size-dependent interaction with HIV-1; the nanoparticles of 1-10 nm close to the virus.…”

Pharmacologic Considerations in Use and Development of Antituberculosis Drugs

“…A number of other promising nanoformulation approaches are also available for this purpose (Pandey et al 2003;Zahoor et al 2005), whereas other groups have instead used subcutaneous or intravenous liposomal or niosomal formulations to target the pulmonary compartment (Adams et al 1999;El-Ridy et al 2007). Alternatively, using nanodispersion or nanoparticle techniques it may be possible to obtain oral formulations of drugs previously only delivered by injection (Pandey and Khuller 2007). Although much work remains to be performed in this area, these technologies have considerable potential to overcome some of the current limitations of drug delivery in tuberculosis.…”

Nanoparticles and microparticles of polymers and polysaccharides to administer fish vaccines

“…For example, PLGA nanoparticles can generally resist the environment of the gastrointestinal tract when administered orally (Li et al, 2008;Pandey & Khuller 2007;Shaikh et al, 2009). Nevertheless, to increase the stability in acid environments a strategy has been developed of polyethylene glycol coating (PEG, Garinot et al, 2007) that decreases interaction with the environment and offers protection from the medium and macrophages (Owens & Peppas 2006).…”